Study the effect of ezetimibe along with metformin on changes in PPAR-? and adiponectin expression, serum levels of liver enzymes, degree of hepatic steatosis, blood glycemic and lipids parameters in non-alcoholic fatty liver grade 2 patients suffering from diabetes: clinical trial

Islamic Azad University of Shahrood0 个研究点目标入组 80 人开始时间: 待定最近更新: 2024年1月22日

适应症

试验速览

暂无简介。

•Type 2 diabetes is known ( under treatment)
•At least one year has passed since their diabetes
•NAFLD grade 2 or 3 has been diagnosed by ultrasound
•All patients should undergo non -pharmacological life style modification treatment

•Newly diagnosed subjects
•Type 1 diabetes
•Receiving only insulin treatment
•Drug intolerance disorders
•Lack of consent to continue treatment
•Diagnosis of type 1 NAFLD
•Having a weight loss of more than 5 %
•Having Infectious diseases , cancer, allergy and immune - based diseases
•Smoking and alcohol consumption
•Appetite disorders such as anorexia or overeating
•Treatment with amphetamine, cyproheptadine, phenothiazine, appetite suppressants or appetite stimulants
•Chronic viral hepatitis (HBV-HCV-HDV), drug-induced liver disease , Wilson's disease , hereditary deficiency of antitrypsin 1, idiopathic hemochromatosis, history of complications from liver diseases including ascites , encephalopathy or variceal bleeding
•Uncontrolled cardiovascular or respiratory disease , active malignancy or active and chronic infections
•The use of agents such as vitamin E- omega 3 fatty acids or drugs with evidence of their effect on NAFLD (pioglitazon , GLP 1analog , dipeptidyl peptidase inhibitors IV ,ursodeoxycholic acid)
•Pregnancy or breastfeeding
•Use of corticosteroids
•Taking herbal medicines whose effect on fatty liver has been proven
•Taking any nutritional supplements in the last 3 months

发起方

Islamic Azad University of Shahrood